DexCom Options Flash Rare Defensive Signal Ahead of Q2 Print

DXCM heads into tonight's Q2 earnings report with options traders flashing their most defensive positioning in nearly a year.

The put/call ratio has climbed to 1.00, more than two standard deviations above its 20-day average of 0.81 — a reading that ranks close to the 52-week high of 1.06. That level of put demand is unusual for DXCM and points to concentrated hedging activity rather than routine pre-earnings caution. The stock has added to the defensive mood with a 4.4% drop on Wednesday alone, leaving it at $71.43 — down roughly 1.8% on the week and 1.4% on the month. Most correlated peers also fell Wednesday, but DXCM's move was sharper: PODD dropped 2.9% and ISRG fell 2.7%, while STE and EW held near flat.

The borrow market tells a much calmer story. Availability is extremely loose at roughly 1,715% — meaning shares available to borrow dwarf the current short position by a wide margin. Borrowing costs have eased sharply, dropping more than 22% over the past week to just 0.47%. Short interest has crept up about 10% over the past month to 4.8% of the free float, but at that level it reflects a measured bearish bet rather than a high-conviction short thesis. The lending conditions offer no squeeze pressure whatsoever.

The analyst debate is squarely about the pace and durability of DexCom's expansion beyond Type 1 diabetes. Bulls point to the company's leadership in CGM technology, meaningful upside from broader coverage of non-intensive Type 2 patients, and a consensus price target of $85.75 — roughly 20% above Wednesday's close. Truist raised its target to $87 just last week, and Mizuho followed earlier in the month at $90, both maintaining positive ratings. Bears flag pricing pressure from payors, competition in the diabetes device sector, and the risk that slower adoption of 15-day sensors and GLP-1 drug tailwinds reduce device demand. The CFO joined a cluster of insiders selling shares in recent months — the Executive Chairman alone sold close to $4 million worth across two July transactions — though these appear to be scheduled disposals rather than a directional call on the business.

The print will test whether DexCom's volume growth in Type 2 is tracking ahead of consensus expectations and whether management's guidance is enough to justify a valuation — currently 26x trailing earnings — that demands visible execution on the expansion story.